Eli Lilly (LLY) PT Raised to $98 at Leerink Partners
Tweet
Share
E-mail
Get Alerts LLY Hot Sheet
Price: $1,208.12 +7.13%
Rating Summary:
30 Buy, 5 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 25
Rating Summary:
30 Buy, 5 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 25
Join SI Premium – FREE
Leerink Partners raised its price target on Eli Lilly (NYSE: LLY) to $98.00 (from $95.00) while maintaining a Market Perform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lilly's Jaypirca gets EU approval recommendation for CLL
- Eli Lilly & Co. (LLY) Declares $1.73 Quarterly Dividend; 0.6% Yield
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
